Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).

Stein MN, Chen YH, Carducci MA, Hudes GR, Lerma PM, Tan WW, Dalune R, Rowland KM, Kuzel TM, DiPaola RS.

Am J Clin Oncol. 2019 Apr;42(4):375-381. doi: 10.1097/COC.0000000000000526.

PMID:
30789412
2.

Comparable safety of 2 aspirin desensitization protocols for aspirin exacerbated respiratory disease.

Pelletier T, Roizen G, Ren Z, Hudes G, Rosenstreich D, Jerschow E.

J Allergy Clin Immunol Pract. 2019 Apr;7(4):1319-1321. doi: 10.1016/j.jaip.2018.08.004. Epub 2018 Aug 23. No abstract available.

PMID:
30144584
3.

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.

Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G.

Clin Genitourin Cancer. 2018 Apr;16(2):e315-e322. doi: 10.1016/j.clgc.2017.10.001. Epub 2017 Oct 16.

4.

Diagnosing environmental allergies: Comparison of skin-prick, intradermal, and serum specific immunoglobulin E testing.

Ferastraoaru D, Shtessel M, Lobell E, Hudes G, Rosenstreich D, de Vos G.

Allergy Rhinol (Providence). 2017 Jun 1;8(2):53-62. doi: 10.2500/ar.2017.8.0194.

5.

Effect of Relocation to the U.S. on Asthma Risk Among Hispanics.

Jerschow E, Strizich G, Xue X, Hudes G, Spivack S, Persky V, Ayala GX, Delamater A, Kim Y, Etzel E, Cai J, Kaplan RC.

Am J Prev Med. 2017 May;52(5):579-588. doi: 10.1016/j.amepre.2016.12.018. Epub 2017 Feb 2.

6.

Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.

Jerschow E, Edin ML, Pelletier T, Abuzeid WM, Akbar NA, Gibber M, Fried M, Lih FB, Gruzdev A, Bradbury JA, Han W, Hudes G, Keskin T, Schuster VL, Spivack S, Zeldin DC, Rosenstreich D.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):998-1007.e2. doi: 10.1016/j.jaip.2016.11.021. Epub 2017 Jan 31.

7.

Eosinophilic esophagitis as possible complication of aspirin treatment in patient with aspirin-exacerbated respiratory disease.

Pelletier T, Tamayev R, Iammatteo M, Nautsch D, Hudes G, Lukin D, Jerschow E.

Ann Allergy Asthma Immunol. 2017 Jan;118(1):120-122. doi: 10.1016/j.anai.2016.10.018. Epub 2016 Nov 16. No abstract available.

PMID:
27865717
8.

Effect of ivermectin on allergy-type manifestations in occult strongyloidiasis.

Rampur L, Jariwala SP, Hudes G, Rosenstreich DL, de Vos G.

Ann Allergy Asthma Immunol. 2016 Oct;117(4):423-428. doi: 10.1016/j.anai.2016.07.021. Epub 2016 Aug 23.

PMID:
27566864
9.

Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease.

Jerschow E, Ren Z, Hudes G, Sanak M, Morales E, Schuster V, Spivack SD, Rosenstreich D.

Ann Allergy Asthma Immunol. 2016 Apr;116(4):321-328.e1. doi: 10.1016/j.anai.2015.12.026. Epub 2016 Jan 25.

10.

Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.

Lee HO, Mustafa A, Hudes GR, Kruger WD.

PLoS One. 2015 Jul 2;10(7):e0131464. doi: 10.1371/journal.pone.0131464. eCollection 2015.

11.

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA.

Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50. doi: 10.1007/s00280-014-2539-0. Epub 2014 Aug 7.

12.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.

Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR.

J Clin Oncol. 2014 Jun 20;32(18):1895-901. doi: 10.1200/JCO.2013.53.2465. Epub 2014 May 12.

13.

PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

MacFarlane AW 4th, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS.

Cancer Immunol Res. 2014 Apr;2(4):320-31. doi: 10.1158/2326-6066.CIR-13-0133. Epub 2013 Nov 25.

14.

Relationship between urine dichlorophenol levels and asthma morbidity.

Jerschow E, Parikh P, McGinn AP, de Vos G, Jariwala S, Hudes G, Rosenstreich D.

Ann Allergy Asthma Immunol. 2014 Jun;112(6):511-518.e1. doi: 10.1016/j.anai.2014.03.011. Epub 2014 Apr 13.

15.

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB.

Oncologist. 2014 Apr;19(4):354-5. doi: 10.1634/theoncologist.2014-0020. Epub 2014 Mar 27.

16.

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.

Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, Schwartz JD, Thompson JA.

Cancer. 2014 Jun 1;120(11):1647-55. doi: 10.1002/cncr.28634. Epub 2014 Feb 27.

17.

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.

de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN.

Clin Cancer Res. 2014 Apr 1;20(7):1925-34. doi: 10.1158/1078-0432.CCR-13-1869. Epub 2014 Feb 17.

18.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ.

Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13.

19.

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).

Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):909-16. doi: 10.1007/s00280-013-2250-6. Epub 2013 Aug 7.

PMID:
23921574
20.

Reply to S. Buti and S. Culine.

Wong YN, Plimack ER, Litwin S, Vaughn D, Lee J, Song W, Hudes GR.

J Clin Oncol. 2013 Apr 20;31(12):1615-6. No abstract available.

21.

Worsening of contact dermatitis by oral hydroxyzine: a case report.

Reid N, Jariwala S, Hudes G, Fodeman J, Jerschow E, Rosenstreich D.

Dermatol Online J. 2013 Feb 15;19(2):4.

22.

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.

Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, Chowdhury S, Dudek AZ, Müller-Mattheis V, Grimm MO, Gschwend JE, Wülfing C, Albers P, Li J, Osmukhina A, Skolnik J, Hudes G.

Invest New Drugs. 2013 Aug;31(4):1001-7. doi: 10.1007/s10637-013-9926-y. Epub 2013 Jan 18.

PMID:
23329066
23.

Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab.

Collins J, Devos G, Hudes G, Rosenstreich D.

J Asthma Allergy. 2012;5:65-70. doi: 10.2147/JAA.S34579. Epub 2012 Nov 8.

24.

Dichlorophenol-containing pesticides and allergies: results from the US National Health and Nutrition Examination Survey 2005-2006.

Jerschow E, McGinn AP, de Vos G, Vernon N, Jariwala S, Hudes G, Rosenstreich D.

Ann Allergy Asthma Immunol. 2012 Dec;109(6):420-5. doi: 10.1016/j.anai.2012.09.005. Epub 2012 Oct 1.

PMID:
23176881
25.

Increased allergic sensitization to mugwort in chronic urticaria.

de Vos G, Kravvariti E, Collins J, Tavdy A, Nazari R, Hudes G, Rosenstreich D.

Dermatology. 2012;225(2):141-6. doi: 10.1159/000342356. Epub 2012 Sep 26.

PMID:
23018776
26.

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G.

J Clin Oncol. 2012 Oct 1;30(28):3545-51. Epub 2012 Aug 27. Erratum in: J Clin Oncol. 2013 Oct 1;31(28):3612.

27.

Chronic urticaria with monoclonal IgG gammopathy: a clinical variant of Schnitzler syndrome?

Patel S, Sindher S, Jariwala S, Hudes G.

Ann Allergy Asthma Immunol. 2012 Aug;109(2):147-8. doi: 10.1016/j.anai.2012.06.001. No abstract available.

PMID:
22840258
28.

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M.

Invest New Drugs. 2013 Jun;31(3):669-76. doi: 10.1007/s10637-012-9857-z. Epub 2012 Jul 25.

PMID:
22828917
29.

Testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):502-35. No abstract available.

PMID:
22491049
30.

Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.

Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G, de Souza P.

Clin Cancer Res. 2012 Jun 1;18(11):3188-96. doi: 10.1158/1078-0432.CCR-11-3137. Epub 2012 Apr 3.

31.

Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA.

J Clin Oncol. 2012 Apr 20;30(12):1371-7. doi: 10.1200/JCO.2011.36.4133. Epub 2012 Mar 19.

PMID:
22430274
32.

A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer.

Beach DF, Somer RA, Hoffman-Censits J, Lin J, Wong YN, Plimack E, Hudes G, Vaughn D, Bernstein GT, Morris GJ.

Semin Oncol. 2012 Feb;39(1):1-8. doi: 10.1053/j.seminoncol.2011.11.001. No abstract available. Erratum in: Semin Oncol. 2012 Apr;39(2):241. Plimeck, Elizabeth [corrected to Plimack, Elizabeth].

PMID:
22289486
33.

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.

Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR.

Eur J Cancer. 2012 Jan;48(1):85-93. doi: 10.1016/j.ejca.2011.10.014. Epub 2011 Nov 28.

PMID:
22129890
34.

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.

Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR.

Ann Oncol. 2012 May;23(5):1234-40. doi: 10.1093/annonc/mdr399. Epub 2011 Sep 19.

35.

Selecting targeted therapies for patients with renal cell carcinoma.

Plimack ER, Hudes GR.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):997-1006; quiz 1007.

PMID:
21917624
36.

Kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):960-77. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Nov 1;9(11):xlv.

PMID:
21917622
37.

Serum amino acid levels as a biomarker for renal cell carcinoma.

Mustafa A, Gupta S, Hudes GR, Egleston BL, Uzzo RG, Kruger WD.

J Urol. 2011 Oct;186(4):1206-12. doi: 10.1016/j.juro.2011.05.085. Epub 2011 Aug 17.

38.

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.

Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S.

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 1:S1-29.

39.

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.

Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K.

Urology. 2011 May;77(5):1166-71. doi: 10.1016/j.urology.2011.01.006.

40.

Association between tree pollen counts and asthma ED visits in a high-density urban center.

Jariwala SP, Kurada S, Moday H, Thanjan A, Bastone L, Khananashvili M, Fodeman J, Hudes G, Rosenstreich D.

J Asthma. 2011 Jun;48(5):442-8. doi: 10.3109/02770903.2011.567427. Epub 2011 Apr 1.

PMID:
21453203
41.

Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.

Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A.

J Clin Oncol. 2011 May 1;29(13):1750-6. doi: 10.1200/JCO.2010.29.2235. Epub 2011 Mar 28.

PMID:
21444868
42.

Subcutaneous allergen immunotherapy in 3 patients with HIV.

Fodeman J, Jariwala S, Hudes G, Jerschow E, Rosenstreich D.

Ann Allergy Asthma Immunol. 2010 Oct;105(4):320-1. doi: 10.1016/j.anai.2010.06.017. Epub 2010 Aug 12. No abstract available.

PMID:
20934633
43.

Global reactivation of epigenetically silenced genes in prostate cancer.

Ibragimova I, Ibáñez de Cáceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, Hudes GR, Ochs MF, Cairns P.

Cancer Prev Res (Phila). 2010 Sep;3(9):1084-92. doi: 10.1158/1940-6207.CAPR-10-0039. Epub 2010 Aug 10.

44.

Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.

Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S.

Pharmacoeconomics. 2010;28(7):577-84. doi: 10.2165/11535290-000000000-00000.

PMID:
20550223
45.

Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma.

Pei J, Feder MM, Al-Saleem T, Liu Z, Liu A, Hudes GR, Uzzo RG, Testa JR.

Genes Chromosomes Cancer. 2010 Jul;49(7):610-9. doi: 10.1002/gcc.20771.

46.

Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG.

Am J Clin Oncol. 2010 Dec;33(6):614-8. doi: 10.1097/COC.0b013e3181c4454d.

PMID:
20142724
47.

Scratching the surface.

Fodeman J, Jariwala S, Hudes G, Wittner M, Klapper P, Liu Q, Rosenstreich D.

Am J Med. 2010 Jan;123(1):22-6. doi: 10.1016/j.amjmed.2009.07.023. No abstract available.

PMID:
20102986
48.

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.

Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.

Semin Oncol. 2009 Dec;36 Suppl 3:S26-36. doi: 10.1053/j.seminoncol.2009.10.013. Review.

PMID:
19963097
49.

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.

Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ.

Am J Clin Oncol. 2010 Dec;33(6):609-13. doi: 10.1097/COC.0b013e3181beac33.

PMID:
20042973
50.

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.

Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabrò F, Cheng S, Trudel GC, Paliwal P, Sternberg CN.

Clin Cancer Res. 2009 Dec 1;15(23):7421-8. doi: 10.1158/1078-0432.CCR-09-1691. Epub 2009 Nov 17.

Supplemental Content

Support Center